The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
ZYME · Healthcare · No moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
| Measure | SLN | XBIT | RVTY | ZYME |
|---|---|---|---|---|
| Moat Score (0–100) | 36 (highest) | 36 (highest) | 36 (highest) | 36 (highest) |
| Methodology version | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 |
| Business trend | 27 | 0 | 15 | 60 (highest) |
| Pricing power | 75 (highest) | 70 | 62 | — |
| Returns on capital | 0 | 0 | 28 (highest) | 6 |
| Balance-sheet safety | 55 (highest) | 55 (highest) | 18 | 55 (highest) |
| Capital allocation | 24 | 57 | 59 (highest) | 24 |
| No price data | No price data | 23% above value if growth stopped today | No price data | |
| Market cap | $1.6B | $69.2M | $12.4B | $1.7B |
| Moat tier | No moat | No moat | No moat | No moat |
| Filing date | FY2025 | FY2025 | FY2025 | FY2025 |